Form 8-K/A - Current report: [Amend]
SEC Accession No. 0001213900-25-065728
Filing Date
2025-07-18
Accepted
2025-07-18 17:04:17
Documents
15
Period of Report
2024-02-08
Items
Item 1.01: Entry into a Material Definitive Agreement
Item 3.02: Unregistered Sales of Equity Securities
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 AMENDMENT NO. 1 TO FORM 8-K ea0249475-8ka_abvcbio.htm   iXBRL 8-K/A 37760
2 FORM OF WARRANT ea024947501ex4-1_abvcbio.htm EX-4.1 17615
3 DEFINITIVE AGREEMENT BETWEEN THE COMPANY AND SHULING JIANG ea024947501ex10-1_abvcbio.htm EX-10.1 32357
4 CONSULTING AGREEMENT ea024947501ex10-2_abvcbio.htm EX-10.2 13196
  Complete submission text file 0001213900-25-065728.txt   288232

Data Files

Seq Description Document Type Size
5 XBRL SCHEMA FILE abvc-20240208.xsd EX-101.SCH 3020
6 XBRL LABEL FILE abvc-20240208_lab.xml EX-101.LAB 34239
7 XBRL PRESENTATION FILE abvc-20240208_pre.xml EX-101.PRE 22362
17 EXTRACTED XBRL INSTANCE DOCUMENT ea0249475-8ka_abvcbio_htm.xml XML 4826
Mailing Address 44370 OLD WARM SPRINGS BLVD. FREMONT CA 94538
Business Address 44370 OLD WARM SPRINGS BLVD. FREMONT CA 94538 510-668-0881
ABVC BIOPHARMA, INC. (Filer) CIK: 0001173313 (see all company filings)

EIN.: 260014658 | State of Incorp.: NV | Fiscal Year End: 1231
Type: 8-K/A | Act: 34 | File No.: 001-40700 | Film No.: 251135110
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)